Pulmonary Arterial Hypertension in a Patient with Multiple Sclerosis Treated with Interferon Beta: A Case Report

Show simple item record

dc.contributor.author Novotná, Alena cze
dc.contributor.author Ehler, Edvard cze
dc.contributor.author Mandysová, Petra cze
dc.contributor.author Jansa, Pavel cze
dc.date.accessioned 2017-05-11T11:17:57Z
dc.date.available 2017-05-11T11:17:57Z
dc.date.issued 2016 eng
dc.identifier.issn 2171-6625 eng
dc.identifier.uri http://hdl.handle.net/10195/67680
dc.description.abstract Pulmonary arterial hypertension (PAH) is characterized by elevation of mean pulmonary artery pressure to values conceivably approaching those seen in the systemic vascular bed. This occurrence is associated with a poor prognosis. PAH may result from a variety of causes, some of which are related to pharmacotherapy. Herein, we present a case of a 39-year-old female patient with relapsing-remitting multiple sclerosis (MS), who was receiving immunomodulatory therapy and subsequently developed severe PAH. We presume a causal relationship between the condition and the patient’s interferon beta therapy, which had spanned 10 years. The interferon beta therapy was stopped because its continued administration could have led to more rapid progression of severe pulmonary hypertension. Due to the severity of pulmonary arterial hypertension, PAH-specific pharmacotherapy was indicated, using sildenafil. Since 1998, only several cases of pulmonary arterial hypertension in patients treated with interferon beta have been documented in the scientific literature. In some of these instances, including in two case studies involving patients with multiple sclerosis, it was concluded that there was a possible association with this therapy. eng
dc.format p. 72-74 eng
dc.language.iso eng eng
dc.relation.ispartof Journal of Neurology and Neuroscience, volume 7, issue: 1 eng
dc.rights open access eng
dc.subject Multiple sclerosis eng
dc.subject Pulmonary arterial hypertension eng
dc.subject Interferon beta sildenafil eng
dc.subject roztroušená skleróza cze
dc.subject plicní arteriální hypertenze cze
dc.subject Interferon Beta sildenafil cze
dc.title Pulmonary Arterial Hypertension in a Patient with Multiple Sclerosis Treated with Interferon Beta: A Case Report eng
dc.title.alternative Plícní arteriální hypertenze u nemocného s roztroušenou sklerózou léčeného interferonem beta: kazuistika. cze
dc.type article eng
dc.description.abstract-translated Pozadí: Plicní arteriální hypertenze (PAH) je charakterizována elevací středního plicního arteriálního tlaku, který se blíží systémovému tlaku. PAH je spojena se špatnou prognózou. Rozvoj PAH je způsoben mnoha faktory a jednám z nich je i farmakoterapie. Kazuistika: 39-letá žena léčena pro relabující-remitující roztroušenou sklerózu (MS) byla po 10 let léčena interferonem beta. Při zjištění PAH byla léčba interferonem beta ukončena, vzhledem k pravděpodobnosti další progrese PAH. Vzhledem k tíži PAH byla zahájen specifická farmakoterapie (sildenafil). V literatuře se od r.1998 popsalo několik kazuistik nemocných léčených interferony, u kterých se vyvinula PAH, z nich 2 byli léčeni pro MS Závěr: Rozvoj PAH byl v důsledku dlouhodobé léčby interferonem beta. cze
dc.peerreviewed yes eng
dc.publicationstatus published version eng
dc.relation.publisherversion http://www.jneuro.com/neurology-neuroscience/pulmonary-arterial-hypertension-in-a-patient-with-multiple-sclerosis-treated-with-interferon-beta-a-case-report.php?aid=8681
dc.identifier.obd 39877936 eng

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account